Is oral nano-curcumin formulation a safe and effective measure for preventing cisplatin-induced nephrotoxicity in cancer patients?

source extracted confidence: high 2026-04-09
#humans #curcumin #cisplatin #male #female

Is oral nano-curcumin formulation a safe and effective measure for preventing cisplatin-induced nephrotoxicity in cancer patients?

Hosseini et al., 2024 | Anticancer Drugs | Rct

Citation

Hosseini Sare, Rahsepar Sara, ... Elyasi Sepideh. Is oral nano-curcumin formulation a safe and effective measure for preventing cisplatin-induced nephrotoxicity in cancer patients?. Anticancer Drugs. 2024-Oct-01;35(9):859-866. doi:10.1097/CAD.0000000000001639

Abstract

Nephrotoxicity is one of the most important complications in cancer patients under treatment with cisplatin-containing regimens. Curcumin, as the most important active component of Curcuma longa, is an antioxidant and anti-inflammatory compound. In this clinical trial, we assessed the preventive effect of nano-curcumin oral formulation against cisplatin-induced nephrotoxicity in cancer patients. In this triple-blind clinical trial 30 cancer patients on cisplatin were randomly included in the treatment group, receiving nano-curcumin 40 mg capsules ( n  = 15) or the placebo group ( n  = 15) twice a day during four chemotherapy courses. Kidney function was measured at the beginning of the study and then at the end of each course of chemotherapy. There was no significant difference in acute kidney injury occurrence rate and creatinine and blood urine nitrogen serum levels between the treatment and placebo groups at the end of each chemotherapy course ( P value >0.05). Just at the end of the first course, the difference was close to significant ( P  = 0.055). We also found no difference in mortality and recurrence rate in an average 30-month follow-up. Nano-curcumin in the prescribed dose and duration was not effective in preventing cisplatin-induced nephrotoxicity in cancer patients in comparison with the placebo. Further studies with larger sample size using different doses and duration of nano-curcumin are recommended.

Key Findings

Further studies with larger sample size using different doses and duration of nano-curcumin are recommended.

Outcomes Measured

  • inflammatory markers

Population

Field Value
Population See abstract
Sample Size 15
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Curcumin
  • Cisplatin
  • Male
  • Female
  • Middle Aged
  • Antineoplastic Agents
  • Neoplasms
  • Adult
  • Administration, Oral
  • Aged
  • Acute Kidney Injury
  • Nanoparticles
  • Kidney Diseases
  • Creatinine

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
  • Vertical: curcumin-cancer

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09